Developing new drugs to target energy production in pancreatic cancer cells
Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer
This study is looking at new medications that can help fight pancreatic cancer by blocking a process that cancer cells use for energy, with the hope that these drugs will work well with current treatments to improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10898760 on NIH RePORTER |
What this research studies
This research focuses on developing first-in-class antagonists that inhibit oxidative phosphorylation (OXPHOS), a critical process for the survival and growth of pancreatic cancer cells. By understanding how these cancer cells rely on OXPHOS for energy, the researchers aim to create more effective treatments that can work alongside existing therapies like gemcitabine. The approach involves designing potent and selective OXPHOS inhibitors that can be taken orally, potentially improving patient outcomes. The study will explore the effectiveness of these new drugs in preclinical models of pancreatic cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer, particularly those whose tumors show high dependence on oxidative phosphorylation.
Not a fit: Patients with pancreatic cancer who do not have a significant reliance on oxidative phosphorylation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown that targeting oxidative phosphorylation can improve survival in pancreatic cancer patients, indicating a promising avenue for further exploration.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Neamati, Nouri — University of Michigan at Ann Arbor
- Study coordinator: Neamati, Nouri
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.